beta
Trial Radar AI
Clinical Trial NCT07487168 for Peritoneal Carcinomatosis is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors Phase 1 24

Not yet recruiting
Clinical Trial NCT07487168 is designed to study Treatment for Peritoneal Carcinomatosis. This Phase 1 interventional study is not yet recruiting. Enrollment is planned to begin on 1 March 2026 until the study accrues 24 participants. Led by H. Lee Moffitt Cancer Center and Research Institute, this study is expected to complete by 1 March 2028. The latest data from ClinicalTrials.gov was last updated on 23 March 2026.
Brief Summary
This single-center, Phase 1 dose-escalation study will evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of pressurized intraperitoneal aerosol chemotherapy with mitomycin C (PIPAC-MMC) for patients with unresectable peritoneal carcinomatosis from gastrointestinal primaries (colorectal, high-grade appendiceal, or small bowel). Up to three PIPAC procedures are planned at 8-week intervals while pat...Show More
Official Title

Phase 1 Single Center Study to Evaluate Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Single Agent Mitomycin C (MMC) in Peritoneal Carcinomatosis (PC) From Solid Gastrointestinal Malignancies (sGI-PC) in Palliative Setting

Conditions
Peritoneal Carcinomatosis
Other Study IDs
  • MCC-23064
NCT ID Number
NCT07487168
Start Date (Actual)
2026-03
Last Update Posted
2026-03-23
Completion Date (Estimated)
2028-03
Enrollment (Estimated)
24
Study Type
Interventional
PHASE
Phase 1
Status
Not yet recruiting
Keywords
Appendiceal cancer
Peritoneal disease
Colorectal cancer
Pressurized Intraperitoneal Aerosolized Chemotherapy
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalMitomycin C Dose Escalation
All participants are assigned to receive PIPAC-MMC. Dose escalation occurs via sequential cohorts using the BOIN model. No participant changes dose once assigned; each receives up to three PIPAC procedures at their assigned dose level.
Mitomycin C (MMC)
Delivered intraperitoneally as aerosol under laparoscopy.
Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
A drug delivery approach in which the antineoplastic agent is delivered directly into the peritoneal cavity solution under laparoscopic pressures (12 mm HG).
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Maximum Tolerated Dose (MTD)
The MTD of PIPAC-MMC will be determined to establish the recommended phase 2 dose (RP2D).
Up to 12 Months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Event-Free Survival (EFS)
From first PIPAC procedure (Day 1) until the earliest of documented disease progression, onset of bowel-obstruction-related clinical deterioration, death from any cause, or end of study follow-up
Up to 24 Months
Quality of Life
Baseline QofL will be recorded with the European Organization for Research and Treatment of Cancer (EORTC) QLQ Core (QLQ-C30) Questionnaire. The survey will be repeated after each of the PIPAC procedures.
Up to 12 Months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Participants must have histologically confirmed peritoneal disease from colorectal, small bowel, or high grade appendiceal adenocarcinoma. High grade appendiceal cancers include moderate or poorly differentiated mucinous or non-mucinous adenocarcinoma, signet ring cell adenocarcinoma, or goblet cell adenocarcinoma. This can be established by image guided biopsy, diagnostic laparoscopy, or previous surgery.
  • Patients must be ineligible for CRS/HIPEC through one of the following criteria: a) PCI score ≥16. b) Inability to achieve complete cytoreduction due to extent of disease. c) Significant small bowel involvement precluding a complete CRS. d) Unresectable disease in porta hepatis, pelvic side wall or other critical structure. e) Patients who decline invasive cytoreduction.
  • Participants must be 18 years of age or older.
  • Participants must have completed at least 4 months of first-line systemic therapy (5-FU based approach with or without biologic therapy).
  • Participants must have Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
  • Participants must have adequate organ and marrow function as defined below: a) absolute neutrophil count ≥1500/mcL. b) platelets ≥100,000/mcL. c) total bilirubin ≤ institutional upper limit of normal (ULN). d) AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN. e) creatinine ≤ 1.5 institutional ULN. or f) glomerular filtration rate (GFR) ≥60 mL/min/1.73 m2.
  • Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should undergo a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification (see Appendix C).

To be eligible for this trial, participants should be class 2B or better.

  • MMC is a known teratogen, for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study drug administration. For women of child-bearing potential a negative urine pregnancy test is required on the morning of surgery.
  • Ability to understand and the willingness to sign a written informed consent document.

  • Participants who have received targeted therapy, immunotherapy, or radiotherapy within 4 weeks (6 weeks for VEGF inhibitors, nitrosoureas or mitomycin C) prior to entering the study.
  • Participants who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1), except for alopecia and chemotherapy induced peripheral neuropathy < 2.
  • Patients with extensive metastatic liver disease (>50% liver volume) are excluded from the trial as are patients with brain metastases. Patients with non-peritoneal metastatic disease are otherwise eligible provided they meet the survival expectations of >6 months.
  • Patients with brain metastases are excluded
  • Patients with bowel obstruction or need for nutritional support (i.e., TPN or tube feeds).
  • Participants who are receiving any other investigational agents or enrolled on other research protocols that may interfere with compliance with requirements of the study.
  • History of allergic reactions or poor tolerance attributed to compounds of similar chemical or biologic composition to MMC, fluoropyrimidines, or anesthesia medications.
  • Participants with uncontrolled intercurrent illnesses.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because MMC is an antibiotic alkylating antineoplastic agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with MMC, breastfeeding should be discontinued if the mother is treated with MMC.
  • Inability to safely perform laparoscopy due to previously noted adhesions or extensive prior surgery which the treating surgeon feels would exclude safe abdominal access.
  • Life expectancy less than 6 months.
  • Patients with history of thromboembolic complications that cannot discontinue for the perioperative duration.
H. Lee Moffitt Cancer Center and Research Institute logoH. Lee Moffitt Cancer Center and Research Institute
Study Central Contact
Contact: Valentina Diaz Aranzazu, 813-745-8536, [email protected]
1 Study Locations in 1 Countries

Florida

Moffitt Cancer Center, Tampa, Florida, 33612, United States
Sean Dineen, MD, Principal Investigator
Trenton Avriett, PA-C, Sub-Investigator
Tiago Biachi de Castria, MD, Sub-Investigator
Kirsten Blue, PA-C, Sub-Investigator
Mintallah Haider, MD, Sub-Investigator
Iman Imanirad, MD, Sub-Investigator
Dae Won Kim, MD, Sub-Investigator
Richard Kim, MD, Sub-Investigator
Chandler Kracht, PA-C, Sub-Investigator
Abigail LaPorta, Sub-Investigator
Satish Maharaj, MD, Sub-Investigator
Kara Miller, PA-C, Sub-Investigator
Allan Lima Perreira, MD, Sub-Investigator
Christopher Ray, PA-C, Sub-Investigator
Tiffany Romershausen, MSN, RN, MPH, Sub-Investigator
Tiffany Valone, PA-C, Sub-Investigator
Michael Wach, MD, Sub-Investigator
James Nguyen, APRN, Sub-Investigator